Publications by authors named "G Cuevas"

Article Synopsis
  • Hepatitis C virus (HCV) microelimination focuses on detecting and treating hidden infections in vulnerable populations, particularly people experiencing homelessness (PEH) who may suffer from substance use disorders, highlighting the role of point-of-care testing and peer support in infection prevention.
  • A study conducted in Madrid from 2019 to 2023 assessed active HCV infection among PEH, utilizing rapid testing methods and analyzing various risk factors, including substance use and financial instability.
  • Out of 2,709 screened PEH, 13.4% tested positive for HCV antibodies, with a prevalence of 6.3% for active infection; key risk factors identified were injection drug use (IDU) and associated behaviors, leading to
View Article and Find Full Text PDF

BackgroundRecent migration trends have shown a notable entry of Latin American asylum seekers to Madrid, Spain.AimTo characterise the profile of asylum-seeking Latin American migrants who are living with HIV in Spain and to outline the barriers they face in accessing HIV treatment.MethodsA prospective cohort study was conducted between 2022 and 2023 with a 6-month follow-up period.

View Article and Find Full Text PDF
Article Synopsis
  • A study in Madrid, Spain, assessed the trends and risk factors of active hepatitis C virus (HCV) infections among people who use drugs (PWUD) from 2017 to 2023, involving 2,264 participants and extensive data collection.
  • Results showed a significant decline in active HCV infection rates from 23.4% to 6.0% in the overall study population, with a notable reduction among those who inject drugs (PWID) and non-injectors.
  • The findings indicate successful prevention and treatment efforts in Madrid, particularly benefiting PWID, highlighting the effectiveness of public health initiatives in controlling HCV infection rates.
View Article and Find Full Text PDF

Background: Cancer patients often have weakened immune systems, resulting in a lower response to vaccines, especially those receiving immunosuppressive oncological treatment (OT). We aimed to assess the impact of OT on the humoral and T-cell response to the B.1 lineage and Omicron variant following COVID-19 vaccination in patients with solid and hematological neoplasms.

View Article and Find Full Text PDF